To integrate and discuss the cutting-edge science and revolutionized therapeutics of cancer in Japan and the United States, JCA (Japanese Cancer Association)-AACR (American Association for Cancer Research) Joint Symposia were held on 25th (Symposium 2) and 26th (Symposium 1) in September 2014 as a part of the 73rd Annual Meeting of the Japanese Cancer Association at Pacifico Yokohama in Yokohama, Japan. The symposia focused on mouse genetics and human genomics in cancer research. Eight prominent scientists from JCA and AACR discussed their own research in the symposia. They provided substantial fruitful information not only for identification of novel target molecules and pathways in cancer therapeutics but also for direct translation of cancer genomics into clinics T he first symposium, "Deeper insights in cancer biology targeting cure," was chaired by Tetsuo Noda (The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan) and Pier Paolo Pandolfi (Beth Israel Deaconess Cancer Center and Harvard Medical School, Boston, MA, USA) (Fig. 1a) . In this symposium, outstanding investigators, two from the USA and two from Japan, presented their works on cancer biology and genetics, and breakthrough advances on how to model the complexity of cancer in the mouse were reported (Fig. 2) .
The second symposium, "Clinical sequencing toward complete cure of cancer," was chaired by Yusuke Nakamura (University of Chicago, Chicago, IL, USA) and Elaine Mardis (The Genome Institute, Washington University, St. Louis, MO, USA) (Fig. 1b) . It featured four speakers from the USA and Japan who have established records of excellence in the field of cancer genomics. The speakers introduced their own recent investigations in cancer treatment through large DNA sequencing efforts and discussed multiple layers of the challenges of translating genomic biology into clinical use (Fig. 3 ).
Symposium 1: Deeper Insight in Cancer Biology Targeting Cure
Molecular biology has provided enormous insight into cancer biology, especially in signal transduction and the cell cycle, which has led to the development of effective targeted drugs. However, patients with metastasizing and ⁄ or recurrent cancers have few drugs that can effect complete cures, which indicates the importance of cancer biology and genetics to elucidate such topics as heterogeneity and plasticity of cancer cells. Four outstanding scientists in this area from JCA and AACR used mouse models of human cancers to present their latest results in cell signaling, identification of driver mutations, and cellular evolution of cancer cells.
Phosphatase and tensin homolog (PTEN) is a potent and well-characterized tumor suppressor. Its mutations are frequently found in PTEN hamartoma tumor syndromes, which include Cowden disease and Bannayan-Zonana syndrome. PTEN is a phosphatase with dual specificity; its lipid phosphatase activity on phosphatidylinositol (3,4,5)-trisphosphate (PtInds(3,4,5)P 3 ) decreases its cellular level, which in turn reduces phosphatidylinositol-3 kinase activity, leading to suppressed tumorigenesis. In addition to mutations and allelic loss, PTEN is downregulated by transcriptional and post-transcriptional mechanisms. Pier Paolo Pandolfi showed that PTEN is also downregulated by several microRNAs. He generated a series of mice with hypomorphic PTEN alleles that express sequentially lower levels of PTEN, which provided evidence that subtle decreases in PTEN levels were sufficient to increase cancer susceptibility. Conversely, mice with hypermorphic PTEN alleles ("super mice") were resistant to tumorigenesis. Based on these results, Dr. Pandolfi proposed a "continuum model for tumor suppression," which reflects PTEN activity levels rather than stepwise changes in copy number. He also discussed how this new model could be integrated with the "two-hit model" previously proposed by Alfred Knudson.
PTEN mutations are classified into three categories, depending on whether they affect protein stability, catalytic activity, or cellular localization. In PTEN hamartoma tumor syndromes, point mutations induce earlier and more aggressive cancers than those caused by allelic loss. Consistent with this, mice harboring G124S or G129E mutations, which abrogate phosphatase activity, showed more aggressive phenotypes than those in null mice, which recapitulate the human PTEN hamartoma tumor syndrome phenotype. Interestingly, Dr. Pandolfi showed that PTEN works as a homodimer or oligomer, which explains why mutant proteins may act dominant-negatively to suppress any remaining PTEN protein function. Dr. Pandolfi proposed that other PTEN mutations (e.g., PTEN K289E mutation, which is found in Cowden disease and affects cellular localization), may also alter wild-type protein in a dominantnegative fashion. Reportedly, PTEN protein not only functions autonomously within cells, but is secreted and taken up by surrounding cells; this raises the possibility that mutant proteins could affect the microenvironment in a dominant-negative fashion.
Inositol polyphosphate-4-phosphatase, type II (INPP4B) is located on chromosome 4q31.21, a region that is frequently deleted in human cancer. It catalyzes dephosphorylation of PtInds(3,4)P 2 to PtInds(3)P. Because PtInds(3,4)P 2 activates Akt, reducing its level works as a tumor suppressor. These observations raise the possibility that INPP4B functions downstream of PTEN and modifies it epistatically. To test this hypothesis, Dr. Pandolfi generated INPP4B-knockout mice and found that, unlike PTEN-knockout mice, they are viable and developmentally normal. They do not develop cancer and only show histiocytic sarcoma after long latency and at incomplete penetrance. However, mice that harbor compound mutations of PTEN À/+ and INPP4B À/À show a distinct tumor spectrum. They develop follicular-like thyroid carcinoma, which are metastatic to lung. Notably, a prevalent tumor in human Cowden syndrome is follicular thyroid cancer; Dr. Pandolfi also showed that PTEN and INPP4B protein and mRNA expression are often both missing in human follicular thyroid carcinoma. These observations collectively show that INPP4B is a tumor suppressor that functions cooperatively with PTEN, but that its function is not solely epistatic to that of PTEN.
Meis1 and Hoxa9 are two major targets of mixed lineage leukemia chimera, and interact in leukemogenesis, but their molecular mechanisms are unclear. Takuro Nakamura (The Cancer Institute, Japanese Foundation for Cancer Research) addressed this issue, using a mouse model for acute myeloid leukemia (AML). In leukemic cells that expressed Meis1 under control of a Cre ⁄ loxP system, he showed Meis1 was dispensable for cell growth and replating activity in vitro, and essential to in vivo leukemogenesis. Further analysis indicated that Meis1 is also required for bone marrow homing and engraftment activity. Dr. Nakamura used ChIP-seq analysis with gene expression profiling, followed by biological testing to identify Sytl1 as a direct downstream target of Meis1. Introducing Sytl1 restored engraftment activity to leukemia cells that lacked Meis1 function. Functionally, activation of Sytl1 stimulated intracellular trafficking of CXCR4 to the plasma membrane, which in turn led to cell migration toward its ligand, CXCL12. Sytl1 also controlled membrane localization of Flt3, a receptor tyrosine kinase. Notably, introducing Sytl1 was sufficient to induce AML in Hoxa9-expressing cells; conversely, its disruption abolished the cooperative function of Meis1 in engraftment.
In humans, Styl1 is coexpressed with AML proteins and its silencing suppresses cell migration. Human AML expression profiling also showed Sylt1 to be frequently associated with Hoxa9, Hoxa7, and Meis1, and correlated Sytl1 expression with poor prognosis. Thus, these findings showed a molecular basis of collaborative function between Meis1 and Hoxa9, and implied a novel treatment strategy.
Lung cancer is a major cause of cancer death worldwide. Mice that harbor conditional mutations to activate K-ras and to inactivate p53 at the same time (KP mice) mirror the phenotypes of human non-small-cell lung cancer; whereas simultaneous conditional loss of p53 and Rb (PR) mimics human small-cell lung cancer. To evaluate the role of the immune system on tumor development, Tyler Jacks (Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA) expressed the luciferase protein fused to T-cell antigen in KP mice and found tumor-reactive T cells to emerge, accompanied by inhibited tumor progression. This reaction occurred for several months, but later was dramatically reduced. As the tumors still expressed the antigen, the suppressed immune response did not occur through immunoediting. Notably, regulatory T cells (Tregs) increased as the tumors started to regrow, which was coincidental to the loss of adequate immune response. Depletion of Tregs led to the emergence of infiltrating T cells; aberrant tumor tissue was observed. These findings show that Tregs profoundly affect immune suppression; this suppression could be the basis of a novel immune therapy. Genome-wide sequence analysis indicates lung cancer has a very high mutation rate. To identify driver mutations, tumor tissues at different stages were taken from mice in a model of PR small-cell lung cancer. Exome and whole-genome sequencing identified about 30 non-synonymous acquired mutations; the predominant mutations were related to the PTEN pathway. Immunohistochemistry showed the focal loss of PTEN expression was associated with Akt phosphorylation, which provided further evidence for activation of this pathway. Additionally, sequence analysis of primary metastasis pairs and primary lymph nodes showed that tumor subclones containing a specific mutation subset were selected for metastasis, indicating clonal evolution. These studies may help to identify mutations that contribute to metastasis.
A CRISPR ⁄ Cas9 system was used to characterize the functions of the mutated genes. Tail-vein injections of plasmid DNA that coded for Cas9 and sgRNA directed to PTEN and p53 simultaneously induced mutations in hepatocytes and led to liver cancer. Bi-allelic mutations were confirmed by deep sequencing. Similar results were obtained by activating a mutation in b-catenin. To further test if this system could be used in lung tissue, a bifunctional lentivirus vector that coded for Cre recombinase and a CRISPR ⁄ Cas9 system that targeted PTEN, Nkx2.1, and Apc were generated, and were transfected to the lungs of KP mice; for each targeted gene, tumor burden and grade increased. These results demonstrate the use of the CRISPR ⁄ Cas9 system as a new way to identify driver genes from numerous mutations reported in human cancers.
Cancer stem cells have highly tumorigenic activity and multidifferentiation potential, and are resistant to various therapeutic interventions. Hideyuki Saya (Institute for Advanced Medical Research, Keio University, Tokyo, Japan) generated induced cancer stem cells of osteosarcoma by introducing cMyc to bone marrow stromal cells obtained from INK4a ⁄ Arfdeficient mice. These cells developed into tumors that were pathologically and clinically similar to human osteosarcomas. Two types of cells were obtained from single-cell cloning. One group, termed AO cells, has trilineage (adipogenic, osteogenic, and chondrogenic) differentiation potential. The other group, called AX cells, has bilineage (osteogenic and chondrogenic) differentiation potential. Syngeneic mice that were inoculated with these cells developed pathologically similar osteosarcoma tissues, but AX cells developed the tumors more quickly, indicating higher tumorigenic activity. Microarray analysis indicated that AO cells expressed embryonic organogenesis genes, whereas AX cells expressed osteocyte commitment genes. Peroxisome proliferator-activated receptor c (PPARc), a master regulator of adipogenic differentiation, is highly expressed in AO cells, but not in AX cells. When PPARc was introduced into AX cells, these clones restored the ability to differentiate into adipogenic cells and exhibited less tumorigenic activity than the parental cells. Furthermore, osteosarcoma tissues derived from these cells after their long latency lost adipogenic differentiation ability. These observations indicate that adipogenic potential negatively regulates tumorigenic activity in osteosarcoma cells.
Adipocyte differentiation is strictly regulated by some defined transcriptional factors, including PPARc and the CCAAT enhancer-binding protein. Cell shape is changed during the differentiation processes, which is mostly controlled by remodeling of the actin cytoskeleton. To address whether transcription factors control actin remodeling or vice versa, multipotent stem cell-like cells (DFAT cells) were used. During the cells' differentiation to adipocytes, actin rearrangement was found to induce PPARc. However, inhibiting actin depolymerization (either by phalloidin treatment or cofilin depletion) blocked PPARc induction, indicating that actin rearrangement is an important signal for adipogenic differentiation. Consistent with this notion, Y27632, a Rho-associated kinase inhibitor that depolymerizes F-actin to produce G-actin, induced both PPARc and lipid droplet accumulation. Similarly, latrunculin A treatment (which produces monomeric actin), but not swinholide A (which produces dimeric actin), sequestered megakaryoblastic leukemia 1 (MKL1) nuclear localization and promoted PPARc expression. A mutant MKL1 that did not interact with monomeric G-actin localized in the nucleus and suppressed PPARc expression. MKL1 depletion induced both PPARc expression and lipid droplet accumulation. In addition, PPARc knockdown kept MKL1 expression high, whereas overexpression of PPARc suppressed MKL1 expression. Thus, it appears that monomeric G-actin interacts with MKL1, which prevents its nuclear localization and allows PPARc expression. In turn, PPARc inhibits MKL1 expression and induces adipogenic differentiation. Treatment of AO cells with Y27632 and troglitazone induces terminal differentiation into mature adipocytes. These observations raise the possibility of developing a novel cancer treatment based on inducing terminal differentiation. aspects of translating large-scale cancer genomics into clinical applications, with particular regard to three topics: (i) her experiences in using genomic information to treat cancer patients; (ii) several bioinformatical tools developed in her laboratory to interpret genomic information; and (iii) recent challenges in clinical translational genomics. Previously, her group discovered a relationship between EGFR mutation and sensitivity to tyrosine kinase inhibitors in non-small-cell lung cancer. She has also contributed to The Cancer Genome Atlas, which has identified cancer type-specific or pan-cancer mutations. She discussed her experiences using genomic technologies to identify molecular targets for individual patients, including a cryptic fusion of PML-RARA oncoprotein in a patient with acute promyelocytic leukemia, and overexpression of FLT3 in an acute lymphoblastic leukemia patient. However, distinguishing "driver" genes from "passengers" and matching drugs to the drivers present obvious difficulties, which the Mardis group is addressing by developing new workflows and data analysis pipelines, exemplified by the Database of Curated Mutations and the Drug Gene Interaction database.
Interpretations of rare somatic variants, such as BRAF inframe insertions, are challenging. Some patients who were treated with a molecular-targeted therapeutic agent that included a tyrosine kinase inhibitor and a BRAF inhibitor developed resistance to the drug in a monotherapy regimen, and therefore needed a combination regimen with genomic monitoring by biopsies. To avoid such acquired resistance, the Mardis group is currently developing a novel immunotherapy approach that uses genomic information from each patient to design highly specific vaccines.
Seishi Ogawa (Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan) discussed efforts to translate knowledge about driver alterations and their detection using clinical sequencing into better understanding of cancer pathogenesis and improved clinical practice in myelodysplastic syndrome (MDS). Previous investigations by his group identified genes for splicing factors, transcription factors, DNA methylation, Ras signaling, and cohesins that were significantly mutated in MDS. Among them, mutations in splicing factors that affect 3 0 splicing recognition in the U2 complex, such as SF3B1, SRSF2, U2AF1, and ZRSR2, were enriched in specific clinicocytological subsets of MDS (refractory anemia with ring sideroblasts, refractory cytopenia with multilineage dysplasia with ringed sideroblasts, refractory anemia with ring sideroblaststhrombocytosis, and chronic myelomonocytic leukemia). The effects of these mutations were reproduced in the RNA splicing process using both an overexpression model and patient samples, but were not seen in cell growth of experimental models such as repopulation assays. In contrast, mutations in some cohesins (STAG2, RAD21, SMC1A, and SMC3) led to increased repopulation capacity of hematopoietic stem cells. Similarly, SETBP1 mutations in the ubiquitin ligase-binding site resulted in immortalization of stem cells in a mouse model. Dr. Ogawa then discussed a study of targeted deep sequencing with a large cohort of 944 MDS cases for gene mutations in 104 known or putative genes related to MDS. A correlation study showed some gene mutations were mutually exclusive or correlative to each other. Analyses of clonal architectures revealed complex intratumor heterogeneity and identified patterns of tumor cell evolution in the occurrence for each mutation in a cell. Prognostic analyses correlated 25 gene mutations with poor outcomes, and that of SF3B1 with better outcomes. They built a prognostic model based on mutational information with clinical parameters, which was superior to a standard model simply based on the International Prognostic Scoring System, and provided a tool for improved diagnosis, biological subtyping, and prognostication for patients.
Broad application of gene-targeted therapies in cancer has been challenging because of the genetic heterogeneity of most cancers, and the lack of therapeutics to target many oncogenic drivers. Jeffrey Tyner (Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA) addressed these challenges in discussing his research program, which aims to integrate functional screens with genomic analyses, and their efforts to efficiently identify druggable genetic lesions. Notably, pathways deregulated by mutated genes might be druggable even if the gene itself is not, as a pathway can be deregulated not only by a simple mechanism (such as a point mutation) but also by complex mechanisms including mutations and altered expression of genes within the pathway. To analyze primary cells from patients with hematologic malignancies, Dr. Tyner's group has developed a functional genomics pipeline, comprised of siRNA and small-molecule libraries to interrogate genes and signaling pathways required for cancer cell growth. The screens are complemented with next-generation sequencing.
Dr. Tyner first presented a proof-of-concept study, in which midostaurin, a JAK2 inhibitor, was found to be effective in treating a patient with chronic myelomonocytic leukemia with a very rare activating mutation of MPL 1886InsGG. He next showed that primary cells from acute lymphoblastic leukemia samples that harbored t(1;19) were consistently sensitive to silencing of the cell-surface receptor ROR1, and to dasatinib, a kinase inhibitor, because of its inhibition of the pre-B-cell receptor signaling complex. Finally, his group identified truncating and membrane-proximal mutations in CSF3R with sensitivity to SFK-TNK2 kinase inhibitors and JAK kinase inhibitors, respectively, in 59% of Philadelphia-negative neutrophilic leukemia. These examples show the efficacy of combining functional genomics with sequencing to identify actionable genetic lesions in individualized medicine. Yusuke Nakamura (Department of Medicine, University of Chicago) discussed the importance of immune response in translational cancer medicine from the aspect of "immunogenomics" or "immunopharmacogenomics" with emphasis on the need to understand complexity in the human immune system. Emerging technologies now allow us to quantify some complex systems in cancer patients by directly counting copy numbers of repertoires for T-cell receptors (TCRs), and by detecting germ-line genetic variations in human leukocyte antigens (HLAs). Such technologies can be applied to many types of disease, including infections and autoimmune-associated diseases; for example, the HLA-B*3505 allele was found to be specifically enriched in patients with skin hypersensitivity to nevirapine, a non-nucleoside reverse transcriptase inhibitor used to treat HIV-1 infection and AIDS. Similarly, their TCR repertoire analysis has elucidated some mechanisms of severe immune reactions, including inflammatory bowel disease and graft-versus-host disease. They have applied this approach to multiple aspects of oncology: monitoring patients who received cancer vaccines, investigating immunological mechanisms of antigen recognition in cancer, predicting therapeutic efficacy, and correlating immune complexity to patient outcomes. They found specific TCRb CDR3 sequences were significantly increased in patients with stable non-small-cell lung cancer after vaccination with cocktails of three different peptides. Differential TCR sequencing with samples from three distinct types of T cells in malignant ascites from ovarian cancer patients showed mutual exclusivity in antigen recognition across T cell types. Breast cancer tissues showed oligoclonal expansion of T cells after neoadjuvant chemotherapy. Finally, Dr. Nakamura described a B-cell lymphoma case with stable disease lasting more than 11 years. The lymphoma cells were found to have somatic mutations in class I and II HLAs with abundant CD4 and CD8 T-cell infiltration, which implies that the HLA mutations facilitate antigen recognition by T cells.
Their approach, based on immunogenomics ⁄ immunopharmacogenomics, characterized the complex nature of the immune microenvironment and linked the complexity to diagnostics and therapeutics for cancer patients.
Conclusions
Both symposia highlighted two of the most important areas of cancer research: mouse genetics and human genomics. In Symposium 1, four outstanding researchers discussed their exceptional mouse models of human cancers. These included a novel concept of tumor suppressors, cellular heterogeneity, and clonal evolutions of cancer tissues, and innovative strategies to identify oncogenic driver genes in vivo. These findings shed light on previously unrecognized target molecules and pathways for cancer therapeutics. In Symposium 2, four prominent experts discussed multiple aspects of translational medical genomics-particularly of interpreting clinically relevant genomic information, such as matching driver mutations to therapeutic drugs with novel workflows, pipelines, and functional genomic tools, and combining immunopharmacogenomics with cancer therapeutics. These efforts will enable direct translation of cancer genomics into clinics.
We believe that all participants were edified by these excellent talks and insights. Finally, we would like to acknowledge the generous support of the Princess Takamatsu Cancer Research Fund, which made it possible to hold these exciting symposia.
